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ABSTRACT
Background and study aims The role of the digital sin-
gle-operator pancreatoscopy (D-SOP) with electrohydraulic
(EHL) or laser lithotripsy (LL) in treating pancreatic ductal
stones is unclear. We investigated the safety and efficacy
of D-SOP with EHL or LL in patients with obstructing pancre-
atic duct stones.
Patients and methods Retrospective analysis of 109 pa-
tients who underwent D-SOP for pancreatic stones at 17
tertiary centers in the United States and Europe from Febru-
ary 2015 to September 2017. Logistic regression was per-
formed to identify factors associated with the need for
more than one D-SOP with EHL/LL.
Results Most patients were males (70.6%),mean age 54.7
years. Fifty-nine (54.1%) underwent EHL and 50 (45.9%)
underwent LL. Mean procedure time was longer in the EHL
group (74.4min vs 53.8 min; P <0.001). Ducts were com-
pletely cleared (technical success) in 89.9% of patients
(94.1% in EHL vs 100% in LL; P=0.243), achieved in a single
session in 73.5% of patients (77.1% by EHL and 70% by LL;
P=0.5).D-SOP failed in 11 patients (10.1%); 6 patients were
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Introduction
Chronic pancreatitis (CP) is associated with pancreatic duct
stones in 50% to 90% of patients [1]. These stones may occur
in the main pancreatic duct (MPD) or side branches (SB), and
contribute to increased intraductal and parenchymal pressure
[1–3]. The composition of pancreatic stones may include an in-
ner nidus of nickel, iron, and chromium surrounded by succes-
sive layers of calcium carbonate. These constituents contribute
to pancreatic stones being harder than bile duct stones, making
endoscopic treatment often challenging, especially when com-
bined with ductal strictures and angulations [1, 3].
The goal of therapy in CP is symptom control and pain relief,
with the aim of decompressing an obstructed main pancreatic
duct and/or removal of obstructing stones. Historically, treat-
ment has been endoscopic or surgical, with endoscopic treat-
ment consisting of ERCP with pancreatic sphincterotomy/endo-
scopic papillary balloon dilation (EPBD), stone extraction using
a retrieval basket and/or retrieval balloon and stent placement.
Surgical treatment usually involves resection and drainage.
Prior studies have shown that both treatments are effective al-
though surgery is longer lasting [2, 3]. Given the challenges in
endoscopic treatment, Extracorporeal shockwave lithotripsy
(ESWL) has been considered lately as the cornerstone treat-
ment modality in symptomatic CP. Multiple studies have shown
MPD clearance after ESWL, alone or in combination with ERCP,
of 59% to 80% and long-term pain relief of 60% to 90% [1, 3, 4].
Per-oral pancreatoscopy (POP) enables direct visualization
of the pancreatic duct. Although it has been available since
the 1990s, it was not popular given technical difficulties, the re-
quirement for two operators, and poor imaging quality. With
the introduction of the single-operator cholangiopancreato-
scopy system (SOCP) (SpyGlass; Boston Scientific, Natick, Mas-
sachusetts, United States) in 2007, the requirement for two op-
erators was solved [5, 6]. Nevertheless, it was underutilized due
to suboptimal fiber optic imaging [7]. The digital version of SOC
(D-SOCP) (SpyGlass DS; Boston Scientific), available since Feb-
ruary 2015, significantly improved image quality compared to
the prior system, possibly increasing its diagnostic and thera-
peutic capabilities [5, 6]. Electrohydraulic lithotripsy (EHL) or la-
ser lithotripsy (LL) can be used during SOCP to achieve stone
fragmentation, enabling complete ductal clearance during
ERCP in a safe and efficient manner [1, 6, 8, 9]. Our group pre-
viously reported the largest cohort of patients with difficult
bile duct stones treated with D-SOC with EHL/LL with 97% effi-
cacy in clearing the bile duct [6]. Presently, POP with EHL/LL is
used mainly as a rescue therapy after failure of ESWL.
A few studies with small sample sizes or using non-digital
pancreatoscopes have assessed the performance of EHL or LL
in treatment of pancreatic stones, with a reported efficacy of
40% to 100% [1, 10–12]. The new digital version of the SOP
with improved image quality possibly aids stone fragmentation
using the available lithotripsy devices. The primary aim of this
study was to assess technical success, defined as pancreatic
duct clearance, in patients with chronic pancreatitis and MPD
stones. Secondary aims were to assess the safety of D-SOP
with EHL or LL and to compare the effectiveness of EHL vs. LL
in the largest cohort of patients with obstructing pancreatic
stones to date.
Patients and methods
This was a retrospective, international, multicenter study in-
cluding 17 tertiary centers (14 from the United States, 3 from
Europe). Institutional Review Board approval was obtained at
all institutions. Medical records were assessed to identify all
consecutive adult patients (> 18 years) who underwent D-SOP
using either EHL or LL for management of obstructing pancreat-
ic duct stones from February 2015 to September 2017.
The study included patients with symptomatic pancreatic
stones, most of whom had prior attempts at stone clearance
using standard ERCP techniques and/or ESWL. Intraductal
stones were diagnosed by abdominal cross-sectional imaging
or prior ERCP. Procedures done with the older version of SOP
or other types of cholangiopancreatoscopes were excluded, as
were all cases of D-SOP without EHL/LL. All procedures were
performed under general anesthesia or propofol deep sedation.
Procedure time was defined as the time between duodeno-
scope scope-in and scope-out. Patients were admitted to hos-
pital for a planned 23-hour observation period after the index
D-SOP. Nevertheless, when clinically appropriate, patients
were discharged after a 1- to 2-hour period of observation.
When the index D-SOP EHL/LL yielded partial or failed stone
clearance, repeated D-SOP was attempted until complete clear-
ance was achieved. The endoscopist determined stone clear-
ance based on final pancreatogram or D-SOP at the time of the
procedure.
The D-SOP (Spyglass DS, Boston Scientific) is a single-use
10.8 French (F) scope with four-way tip maneuverability, dedi-
cated irrigation and aspiration channels, and one 1.2-mm work-
ing channel. It has enhanced visualization with a digital sensor
[4, 5, 7].
Several lasers have been developed. Laser light at a particul-
ar wavelength is focused on the surface of the stone to induce
treated with extracorporeal shockwave lithotripsy (ESWL), 1
with surgery,1 with combined treatment (ESWL+D-SOP
EHL) and 3 with other. Fourteen adverse events occurred in
11 patients (10.1%). Patients with more than three ductal
stones were more likely to have technical failure compared
to those with less than three stones (17% vs. 4.8%; P=
0.04). Having more than three stones was independently
associated with the need for more than one D-SOC EHL/LL
session (OR 2.94, 95% CI 1.13–7.65).
Conclusion D-SOP with EHL or LL is effective and safe in
patients with pancreatic ductal stones.
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wave-mediated fragmentation [1]. In this study, the VersaPulse
P20, Slim line 365-µm fiber Holmium laser (Ho:YAG) (Lumenis
Inc., San Jose, California, United States) was used. The power
setting was maximum 20W (starting at 1 J and 10Hz then rising
to 2.5 J × 8Hz), in bursts of 5 seconds. Stone fragments were
retrieved by standard techniques (▶Fig. 1) (▶Supplemental
Video 1).
EHL is a bipolar 1.9 F probe that discharges sparks with the
aid of a charge generator (AUTOLITH, Northgate Technologies
Inc., Illinois, United States) in an aqueous medium (normal sal-
ine). The probe is positioned 1 to 2mm from the stone. The
spark produced under the saline medium generates high-fre-
quency hydraulic pressure waves, absorbed by nearby stones
resulting in their fragmentation. Shock waves are delivered in
brief pulses, ranging from a single discharge to continuous fir-
ing [1, 5]. The stone fragments were retrieved by conventional
ERCP techniques. The power settings in the generator ranged
between low/medium/high (50–100%) and delivered over 1-
to 2-second bursts (▶Fig. 2) (▶Supplemental Video 2).
The type of lithotripsy device used in the current study was
chosen solely based on endoscopist preference and the center’s
availability.
Outcomes and definitions
The primary study outcome was rate of technical success, de-
fined as complete pancreatic duct clearance. Safety of D-SOP
using either EHL or LL was defined by the rate and severity of
adverse events (AEs) as graded per the ASGE lexicon (mild,
moderate, severe, fatal) [13]. Other outcomes included clinical
success (defined by resolution or improvement of symptoms),
number of D-SOP with EHL/LL sessions needed to clear the
MPD, need for other therapies (ESWL or surgery), incomplete
stone removal/stone recurrence and procedure time. Compari-
son of outcomes between EHL vs. LL was also assessed.
Statistical analysis
Descriptive statistics was presented as frequencies (%) for cate-
gorical variables and mean ± standard deviation (SD) or median
(interquartile range [IQR]) for continuous variables. Chi-square
test and Fisher’s exact test were used to compare categorical
data while Student’s t-test and Wilcoxon rank-sum test were
used for continuous data, as appropriate. A P value≤0.05 was
considered statistically significant. Logistic regression analysis
was performed to identify factors associated with the need for
more than one session of D-SOP with EHL/LL. Statistical analysis
was performed using Stata software (Stata version 14.1, Col-
lege Station, Texas, United States).
Results
A total of 109 patients (71% male, mean age 54.7 ± 15.0 years)
underwent D-SOP with EHL or LL for pancreatic ductal stones.
Most common presenting symptoms were abdominal pain
(96.3%) and/or weight loss (51.4%). Diabetes was present in
48.6%; 74.3% were on pancreatic enzymes and 74.3% on
opioids. Most patients (88.1%) had prior ERCP attempts and a
minority (11%) prior ESWL session(s) with failed ductal clear-
ance. The most frequent prior intervention was stone extrac-
tion using a retrieval balloon (73.4%). Seventy-four patients
(67.9%) had a plastic pancreatic stent placed during a prior
failed ERCP. Mean MPD diameter by prior imaging was 9.2 ±
3.5mm (▶Table 1).
During the index D-SOP, all patients had successful MPD can-
nulation with the D-SOP. Image quality of stone visualization
▶ Fig. 1 63-year-old female with history of alcohol induced chron-
ic pancreatitis. Patient has recurrent post prandial abdominal
pain. CT scan showed dilated MPD with stones. a ERCP showing a
dilated, tortuous MPD with multiple filling defects at the genu/
body. b Intraductal pancreatic stone seen on pancreatoscopy.
c Ho:YAG lasers’ probe green light on the surface of the stone.
d Final ERCP pancreatogram showing decompressed MPD without
filling defects.
Video 1 DSOP with LL for treatment of MPD stone.
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was reported as excellent in 67.9% of cases and good in 30.3%.
In two cases (1.8%), visualization was reported as poor, with
stones located in the MPD and side branches. The majority of
stones were located in the head of pancreas (HOP) (49.5%), fol-
lowed by the neck/genu (21.1%), body (13.8%), tail (5.5%), and
10.1% were multifocal. Almost half of the cohort had more than
three stones (43.2%). Most stones (56.9%) measured between
1 and 9mm and 61.5% were impacted. Most patients (78%)
had a downstream MPD stricture, the majority (87.1%) of
whom required stricture dilation to perform lithotripsy. After
EHL or LL, the most common device used for stone extraction
was the extraction balloon (83.5%). Stents were placed after
D-SOP in 98.2% of patients. Mean procedure time (available in
78% of patients) was 62.8 ±23 minutes (▶Table1).
Outcomes
Complete ductal clearance using EHL/LL (technical success) was
achieved in 89.9% of patients, and in 73.5% was accomplished
in a single session (▶Table 2). Overall, success rates were sim-
ilar among tertiary centers participating in this study. Half of
patients needing more than one session had more than three
stones (15/26), and stones were larger than 10mm in 53.8%
(14/26). Moreover, 81% of these patients (21/26) had a down-
stream stricture (i. e. between the ampulla and the stone). Ele-
ven patients (10.1%) failed DSOP and were treated with surgery
(n =1), ESWL alone (n =6), combined treatment with ESWL/D-
SOP EHL (n=1) and other (n =3) (ERCP/balloon sweep and
stenting n=2, awaiting treatment n=1). Reported reasons for
technical failure were: failed stone fragmentation (n=3), failure
to advance EHL probe to the site of the stone (n =3), failure to
advance the D-SOP due to angulation/tight stricture (n =3) and
unspecified reason (n =2). Of the 11 patients with technical
failure, three were attributed to failure of stone fragmentation
by EHL. There were no failures of fragmentation in the LL
group. Patients with technical failure had more than three
stones (8/11), impacted stones (7/11) and a downstream stric-
ture (6/11). Of the 11 patients with technical failure, one re-
quired surgery (Puestow procedure). This patient had more
than three ductal stones, impacted stones, and a downstream
stricture. Clinical success was achieved in 88.4% of the patients.
Fourteen adverse events (AEs) occurred in 11 patients
(10.1 %) including five pancreatitis, one MPD perforation, two
bleeding, three fever and three abdominal pain without pan-
creatitis. These were rated as mild (n =12, 85.7%) and moder-
ate (n=2, 14.3%), per ASGE lexicon. Ten patients (10/11) with
AEs were admitted to the hospital. Most were treated conserva-
tively with intravenous fluids, pain medication, and antibiotics,
while five (5/11) were treated endoscopically with repeated
ERCP and stent placement/exchange.
Predictors of outcomes
Patients with more than three stones were more likely to have
technical failure compared to those with less than three stones
(17% vs. 4.8%, P=0.04). Similarly, patients with more than
three stones were more likely to need more than one D-SOP
EHL/LL session (38.5% vs. 18.6%, P=0.03). Multivariable analy-
sis was not possible for technical failure due to the small num-
ber of events (n=11). On the other hand, the only factor asso-
ciated with the need for more than one session of D-SOP EHL/LL
was having more than three ductal stones (OR 2.94, 95% CI
1.13–7.65), independently to the type of procedure (EHL vs.
LL) and the age of the patient (▶Table3).
▶ Fig. 2 33-year-old male with recurrent acute on chronic pan-
creatitis secondary to heterozygous SPINK1 N34S mutation. On
CT scan, a stone located in the MPD at the level of the pancreatic
body with upstream ductal dilation was noted. a ERCP showed a
mildly dilated and tortuous MPD with side branches widening. The
distal body/tail is not visualized despite high quality pancreato-
gram and attempts to pass the wire distally were unsuccessful.
b The pancreatoscope was advanced over the wire to the area that
was not well visualized. c A round stone was seen on pancreato-
scopy. EHL probe advanced. d Fragments of the stone post litho-
tripsy.
Video 2 DSOP with EHL for treatment of MPD stone.
Brewer Gutierrez Olaya I et al. Safety and efficacy… Endoscopy International Open 2019; 07: E896–E903 E899
▶ Table 1 Patient baseline characteristics.
Total (N=109) EHL (N=59) LL (N=50) P value
Female sex; n (%) 32 (29.4) 23 (39) 9 (18) 0.02
Mean age (mean ± SD) 54.7 ± 15 56±16 53±13 0.3
Symptoms
Abdominal pain; n (%) 105 (96.3) 56 (94.9) 49 (98) 0.62
Weight loss; n (%) 56 (51.4) 16 (27.1) 40 (80) < 0.001
On pancreatic enzymes; n (%) 81 (74.3) 37 (62.7) 44 (88) 0.003
Opioid use; n (%) 81 (74.3) 39 (66.1) 42 (84) 0.05
Diabetes; n (%) 53 (48.6) 20 (33.9) 33 (66) 0.001
Exocrine pancreatic insufficiency; n (%) 46 (42.2) 15 (25.4) 31 (62) < 0.001
Prior ESWL 12 (11) 10 (16.9) 2 (4) 0.03
Patients from community (not center) 68 (62.4) 26 (44.1) 42 (84) < 0.001
Prior ERCP with failed stone extraction; n (%) 96 (88.1) 46 (78) 50 (100) < 0.001
Prior interventions for stone removal
Balloon extraction; n (%) 80 (73.4) 36 (61) 44 (88) 0.001
Retrieval basket; n (%) 13 (11.9) 8 (13.6) 5 (10) 0.57
EHL; n (%) 10 (9.2) 4 (6.8) 6 (12) 0.51
LL; n (%) 6 (5.5) 0 (0) 6 (12) 0.008
Prior surgery; n (%) 1 (0.9) 1 (1.7) 0 (0.0) 1
Indwelling pancreatic stent; n (%) 74 (67.9) 42 (71.2) 32 (64) 0.54
Main pancreatic duct size; (mean ± SD) (mm) 9.2 +3.5 8.3 +2.9 10.1 +3.9 0.008
Stone location 0.16
Head; n (%) 54 (49.5) 35 (59.3) 19 (38)
Neck; n (%) 23 (21.1) 10 (16.9) 13 (26)
Body; n (%) 15 (13.8) 6 (10.2) 9 (18)
Tail; n (%) 6 (5.5) 4 (6.8) 2 (4)
Multifocal; n (%) 11 (10.1) 4 (6.8) 7 (14)
Stone size (largest) 0.04
<10 mm; n (%) 62 (56.9) 40 (67.8) 22 (44)
10– 19 mm; n (%) 32 (29.4) 13 (22) 19 (38)
> 20 mm; n (%) 15 (13.8) 6 (10.2) 9 (18)
More than 3 stones in MPD; n (%) 47 (43.1) 30 (50.8) 17 (34) 0.077
Stone impaction; n (%) 67 (61.5) 26 (44.1) 41 (82) < 0.001
Main pancreatic duct stricture; n (%) 85 (78) 39 (66.1) 46 (92) 0.001
Devices used for stone extraction 0.02
Extraction balloon 91 (83.5) 44 (74.6) 47 (94)
Retrieval basket 5 (4.6) 5 (8.5) 0 (0)
Other 2 (1.8) 2 (3.4) 0 (0)
Balloon+ Basket 7 (6.4) 4 (6.8) 3 (6)
None 4 (3.7) 4 (6.8) 0 (0)
EHL, electrohydraulic lithotripsy; LL, laser lithotripsy; SD, standard deviation; ERCP, endoscopic retrograde cholangiopancreatography; MPD, main pancreatic duct
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Incomplete stone removal/recurrent stones
Median follow-up time was 210 days [IQR:68–387]. Patients
with technical failure or those lost to follow-up were not includ-
ed in this aspect of the analysis (20/109). After the index D-SOP
EHL/LL, 86.7% required at least an additional ERCP for stent re-
moval/stent replacement and/or stricture dilation, and 13.4%
are waiting for a follow-up ERCP. Incomplete stone clearance/
recurrent stones was seen in nine of 89 patients (10%) after a
median follow-up time of 105 days [IQR:85–471.5]. Most of
these patients had more than three stones and stone location
was in the neck/genu, body, tail or multifocal (6/9).
Management of incomplete stone removal/ recurrent stones
was performed with ERCP with extraction balloon (n=4,44.4%),
repeated D-SOC with EHL/LL (n =1,11.1%), ESWL (n=1,11.1%),
no treatment/expectant conduct (n =2,22.2%) and in one pa-
tient (11.1%) treatment was not specified (▶Table2).
▶ Table 2 Procedure outcomes.
Total (N=109) EHL (N=59) LL (N=50) P value
Technical success (pancreatic duct clearance); n (%) 98 (89.9) 48/511 (94.1) 50 (100) 0.243
Clinical Success; n (%), n =95 84 (88.4) 40 (88.9) 44 (88) 1
Number of EHL/LL sessions to clear pancreatic duct; n (%) (n =98) 0.5
1 72 (73.5) 37 (77.1) 35 (70)
2–3 23 (23.5) 9 (18.8) 14 (28)
More than 3 3 (3.1) 2 (4.2) 1 (2.0)
Number of additional ERCPs for dilation/removing stents; n (%) (n = 90) <0.001
None 12 (13.3) 12 (27.3) 0 (0.0)
1 52 (57.8) 19 (43.2) 33 (71.7)
2–3 17 (18.9) 8 (18.2) 9 (19.6)
More than 3 9 (10) 5 (11.4) 4 (8.7)
Stone recurrence; n (%) (n = 89) 9 (10.1) 6 (14) 3 (6.5) 0.3
Management of stone recurrence (n =9) 0.36
Balloon/basket; n (%) 4 (44.4) 3 (50) 1 (33.3)
Cholangioscopy with EHL/LL; n (%) 1 (11.1) 1 (16.7) 0 (0)
ESWL; n (%) 1 (11.1) 0 (0) 1 (33.3)
Other; n (%) 1 (11.1) 0 (0) 1 (33.3)
None; n (%) 2 (22.2) 2 (33.3) 0 (0)
Procedure time (min) (mean ± SD) (n = 85) 62.8 +23 74.4 ± 25.5 53.8 ±16.2 < 0.001
Number of patients with adverse events; n (%) (n = 11) 11 (10.1) 5 (8.5) 6 (12) 0.54
Median follow up time; days median (IQR) 210 (68–387) 157 (63–353) 291 (141–410) 0.005
Median time to recurrence; days (IQR) (n =9) 105 (85–471.5) 91 (76.25–205.5) 448 (105– 2) 0.5
EHL, electrohydraulic lithotripsy; LL, laser lithotripsy; ESWL, extracorporeal shockwave lithotripsy; SD, standard deviation.
1 Eight technical failures were due to reasons not specific to the EHL procedure per se and thus were excluded from the comparison of EHL vs LL in technical success.
2 There were only three recurrences. There is no interquartile range.
▶ Table 3 Factors associated with the need of more than one DSOP
with EHL/LL.
Factors More than one D-SOP with EHL/LL
(n=26)
Odds Ratio (95% CI) P value
EHL vs. LL 0.64 (0.24–1.67) 0.36
More than 3 ductal
stones
2.94 (1.13–7.65) 0.04
Age >55 years 0.42 (0.16–1.09) 0.08
EHL, electrohydraulic lithotripsy; LL, laser lithotripsy
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EHL vs. LL
Technical success was higher in the LL group (100% vs. 94.1%,
P=0.243), although the difference was not significant. EHL pro-
cedures were significantly longer than those where LL was uti-
lized (74.4±25.5min. vs. 53.8±16.2min, P <0.001). On the
other hand, the number of patients with AEs were not signifi-
cantly different between the two groups (8.5% vs 12%, P=
0.54). Moreover, in both groups, most patients needed one ses-
sion to achieve MPD clearance (70.0% vs. 77.1%, P=0.49) and
clinical success was similar as well (88 vs 88.9%, P=1) (▶Ta-
ble2).
Discussion
Endoscopic management of pancreatic ductal stones can be
challenging, due to stone size, density, and location. Small and
floating calculi less than 5mm can be extracted by standard
techniques of ERCP with pancreatic sphincterotomy followed
by balloon trawl or basket. Stones greater than 5mm are often
impacted and difficult to extract using standard techniques [3].
Reported rates of stone clearance using the basket have been as
low as 9% [3, 14]. Larger, impacted pancreatic stones require
pre-extraction fragmentation using ESWL or other lithotripsy
method, EPBD or surgical procedures. Factors that decrease
the rate of endoscopic clearance include surgically altered
anatomy, strictures, ductal angulation, and impacted stones
[1]. ESWL alone or in combination with ERCP is reported to
have an efficacy in clearing pancreatic stones of 59% to 80%
[1]. Nevertheless, there are no definitive data on the number
of sessions needed, and a subsequent ERCP is often performed
after the last session to clear stone fragments, treat strictures,
and place a stent, incurring additional costs. The rate of AEs of
ESWL has been reported between 5.8% and 6.7% [1, 2]. Com-
plications include pain and ecchymosis at the site of shock-
wave, abdominal pain, and fever. Rare AEs include perirenal he-
matoma, biliary obstruction, splenic rupture, bowel perfora-
tion, liver trauma, and necrotizing pancreatitis [1, 2]. Moreover,
ESWL units are not typically within the endoscopy unit, requir-
ing inter-departmental referrals, potentially delaying therapy.
D-SOC EHL/LL has been reported to be highly effective and
safe in treating difficult bile duct stones [6] and previous small
studies/case reports using POP in management of pancreatic
stones have shown acceptable rates of success and safety [7,
10, 12]. The introduction of the D-SOC has improved the ease
of SOC and markedly improved image quality. These have led
to a greater utilization of EHL or LL in the ERCP armamentarium
for management of difficult biliary and now pancreatic stones.
The largest study to date on SOP-LL in management of pan-
creatic stones was published by Atwell et al [12]; a retrospective
multicenter study including 28 patients, with 79% complete
ductal clearance and 11% partial stone clearance rate. Stone
clearance was achieved in one session in 61% of patients and
AEs were noted in 29% of patients (post-ERCP pancreatitis and
abdominal pain). A median of two stones sized 15mm were
identified in the head (32%), neck (11%), body (32%), tail
(4 %), or multifocal (21%); stone clearance was greater when
stones were located in the head (92%) compared to the tail
(67%). Main limitations of the study were small number of pa-
tients included and lack of information regarding reasons of
prior ERCP or ESWL failures.
A systematic review performed by Beyna et al [1], assessed
the efficacy and safety of POP-guided EHL and LL in pancreatic
stones, including both SOP versions (DS and Legacy) and other
types of pancreatoscopes, with a total of 87 patients. The rate
of successful ductal clearance was 43% to 100% with 0% to
13.5% AEs. Limitations were the heterogeneity of the studies
and the variation in the type of pancreatoscopes.
Our multicenter study is the largest to date on use of D-SOP
with EHL or LL in management of pancreatic stones, showing
high efficacy and safety. Ductal clearance was seen in 89.9% of
patients, and in 73.5% was achieved in a single session. Clinical
success was seen in 88.4% of patients. AEs were seen in 10.1%
of patients, the majority of which were pancreatitis (n =5),
bleeding (n=3) and abdominal pain (n =3), and managed con-
servatively in the majority of cases. When comparing EHL to LL,
most outcomes were similar except for procedure time, which
was longer in the EHL group, with statistical significance
(74.4 min vs. 53.8min, P <0.001). Pancreatic stones are often
harder than bile duct stones (i.e Hounsfield index >2000 HU).
The advantage of LL over EHL in terms of rate of success and re-
quiring less procedure time theoretically could be explained by
the ability of LL to fragment denser stones [10, 12]. Neverthe-
less, it is worth noting that LL technology is more expensive
than EHL. Moreover, we need larger studies to validate our re-
sults. Regarding AEs, both techniques have similar AEs profiles,
more frequent when compared to cholangioscopy and litho-
tripsy, mainly due to the higher risk of post ERCP pancreatitis,
which is similar to risk of pancreatitis after standard pancreatic
ERCP techniques (7–15%). Independently of the chosen litho-
tripsy technique, it is important to avoid long periods of pan-
creatic duct exposure to high energy levels in a single session,
given the risk of thermal injury to the ductal wall.
Limitations of this study are its retrospective nature, intro-
ducing possible selection bias. Although we collected informa-
tion about prior procedures before D-SOP-EHL/LL, the choice of
first-line treatment of pancreatic stones varies among centers
and future randomized controlled trials comparing convention-
al ERCP techniques to ESWL and D-SOP EHL/LL are needed to
clearly define the exact role and timing of this technique. Also,
there was lack of information regarding the reasons for ERCP/
ESWL failures. Both groups differed in baseline characteristics
which could affect the observed differences in outcomes. In ad-
dition, there were no objective measurements to assess pain or
other symptoms before and after the procedure, making it dif-
ficult to accurately define the effect of D-SOP EHL/LL on symp-
tom resolution. Even though our analysis showed that there are
certain factors that could be associated with failure of D-SOP,
the low number of patients with technical failure (n=11) and
the fact that there were no LL failures did not provide enough
power to identify significant factors by multivariable analysis.
Nevertheless, to our knowledge, this is the largest multicenter
study on D-SOP with EHL/LL to date, involving 17 tertiary insti-
tutions. Our results may only be applicable to tertiary centers
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with high experience in chronic pancreatitis and D-SOP. Addi-
tionally, given the costs of these technologies, cost-effective-
ness analysis comparing both techniques to ESWL and surgery
is warranted.
Conclusion
In conclusion, D-SOP with either EHL or LL may represent an ef-
ficient, safe, and minimally invasive alternative to ESWL and
surgical approaches in management of obstructing pancreatic
ductal stones. When comparing both techniques, they have
similar efficacy and safety profile.
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